Key Drivers
- Strong balance sheet
- Persistent cash burn
- Weak profitability
AIAI Summary
TNGX has shifted from a speculative platform story to a more credible late-stage biotech play after strong vopimetostat data in MTAP-deleted, RAS-mutant pancreatic cancer, but investors should treat it as a high-upside, high-risk name because value now hinges on clean Phase 3 execution while persistent losses, negative cash flow, and dilution risk remain overhangs.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong balance sheet
- •Persistent cash burn
- •Weak profitability
TNGX has exceptionally strong liquidity and low leverage, but ongoing revenue weakness, heavy losses, and continued cash burn make the business dependent on external financing.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Weak bounce
- •Support holding
TNGX remains in a short-term downtrend with weak bounces, but $25.60 support is still holding and a reclaim of $27.70 would be the first sign of improvement.
Sharp drop from $29.00 on 2026-08-06 followed by quick-failing rallies
Sentiment & News
Key News Insights:
- •Analyst Upside
- •Earnings Miss
- •Leadership Change
Tango Therapeutics saw strong analyst support and upside estimates, but near-term sentiment weakened after a Q2 earnings miss, higher expenses, and an executive leadership change.
The stock's near-term performance may stay pressured until Tango shows better cost control and earnings execution
Similar Companies in Healthcare
Other companies in the same sector with AI ratings